Summary
This project aims to understand how extracellular sialylation of IgG, particularly IgG1 and IgG3, regulates immune responses and exerts anti-inflammatory activity, with the goal of developing new antibody-based therapies.
Harnessing the anti-inflammatory activity of extracellular sialylation of IgG.
US · IL
National Institutes of Health
grant
awarded
#nih-5R01AI155662-05
What they want
The research will investigate the regulation of extracellular IgG sialylation during autoimmune disease, specifically focusing on how B4ST6Fc reduces SLE nephritis via sialylation of pathogenic IgG1 and IgG3. It will also identify the molecular determinants responsible for the anti-inflammatory activity of sialylated IgG, hypothesizing a specific amino acid sequence in IgG1 and IgG3 combined with N297 sialylation enables DC-SIGN binding and anti-inflammatory effects.
Deliverables
- Understanding of the regulation of extracellular IgG sialylation during autoimmune disease
- Identification of molecular determinants of sialylated IgG anti-inflammatory activity
- New insights into IgG biology
- Potential for development of innovative antibody-based therapies
Technical requirements
- Biophysical experiments
- In vitro functional assays
- In vivo functional assays
Market context
inferred from NAICSProfessional, Scientific & Technical Services
NAICS 541714
- US market size
- $2.0T
- Typical award
- $25K – $50M
Typical buyers
All federal civilianDoDStates
Commonly required
8(a)WOSBSDVOSBPE/PMP
Sector-level estimate — full code lookup not yet in catalog.
